Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 20/20 | 0.56 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | LOX | P28300 | 2/20 | 0.48 |
| ▸ | LOXL3 | P58215 | 2/20 | 0.48 |
| ▸ | LOXL1 | Q08397 | 2/20 | 0.48 |
| ▸ | LOXL4 | Q96JB6 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19255113 | 0.92 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL20699687 | 0.92 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL20699639 | 0.91 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL20699641 | 0.91 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255719 | 0.88 | LOXL2 (0.56) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255186 | 0.87 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255595 | 0.86 | LOXL2 (0.64) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255078 | 0.85 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255081 | 0.85 | LOXL2 (0.67) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255217 | 0.84 | LOXL2 (0.52) | LOXL2DAOAOC3LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017136870-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |